Regulation of the Hypothalamic-Pituitary-Adrenal Axis

NeuroImmunoModulation - Tập 16 Số 5 - Trang 265-271 - 2009
Anastasios Papadimitriou1, Kostas Ν. Priftis2
1Third Department of Pediatrics, University of Athens School of Medicine, Attikon University Hospital, Haidari, Athens, Greece. [email protected]
2National and Kapodistrian University of Athens

Tóm tắt

Glucocorticoids (GCs) are essential for the maintenance of homeostasis and enable the organism to prepare for, respond to and manage stress, either physical or emotional. Cortisol, the principal GC in humans, is synthesized in the adrenal cortex. It is released in the circulation in a pulsatile and circadian pattern. GC secretion is governed by hypothalamus and pituitary. The hypothalamus senses changes in the external and internal environment that may disrupt the homeostatic balance of the organism (i.e. stressors), and responds by releasing corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) from parvocellular neurons projecting from the paraventricular nucleus to the median eminence. These neurohormones are released into the anterior pituitary where they act synergistically via specific receptors (CRH-R1 and V1B receptor, respectively) to trigger the release of the adrenocorticotropic hormone (ACTH) from the corticotrope cells into the systemic circulation. In turn, ACTH exerts its actions on the adrenal cortex via specific receptors, type 2 melanocortin receptors (MC2-R), to initiate the synthesis of cortisol, which is released immediately into the systemic circulation by diffusion. Hypothalamic CRH and AVP, pituitary ACTH and adrenal GCs comprise the hypothalamic-pituitary-adrenal (HPA) axis. In this brief review, the HPA axis and the various factors that regulate its function are described.

Từ khóa


Tài liệu tham khảo

10.1210%2Fme.2006-0303

10.1210%2Fer.2003-0030

10.1016%2FS0889-8529%2805%2970208-5

10.1038%2F138032a0

10.1152%2Fphysrev.00041.2006

10.1001%2Fjama.267.9.1244

10.1210%2Fedrv-5-1-25

10.1016%2F0303-7207%2892%2990091-J

10.1016%2F0006-8993%2888%2990523-9

10.1056%2FNEJM199505183322008

10.1126%2Fscience.6267699

10.1530%2Feje.1.02247

10.1038%2F452

10.1073%2Fpnas.90.19.8967

10.1073%2Fpnas.92.3.836

10.1210%2Fer.2005-0034

10.1210%2Fme.12.8.1077

10.1016%2Fj.peptides.2004.05.025

10.1016%2Fj.tem.2007.12.002

10.1016%2Fj.peptides.2004.03.027

10.1210%2Fjc.78.1.73

10.1016%2FS0092-8674%2801%2900282-3

10.1210%2Fjcem-58-2-298

10.1210%2Fjcem-55-6-1035

10.1210%2Fjcem-57-3-592

10.1210%2Fen.2005-1649

10.1016%2F0031-9384%2895%2900058-Q

10.1016%2F0143-4179%2895%2990112-4

10.1046%2Fj.1365-2265.1999.00828.x

10.1210%2Fjc.84.7.2489

10.1124%2Fpr.58.1.4

10.1210%2Fer.17.1.64

10.1172%2FJCI118615

10.1016%2FS0893-133X%2800%2900236-0

10.1016%2Fj.pharmthera.2005.06.022

10.1210%2Fme.7.8.1031

10.1172%2FJCI117813

10.1081%2FERC-120016797

10.1074%2Fjbc.274.39.27857

10.1080%2F10253890701292119

10.1038%2Fsj.bjp.0706456

10.1210%2Fedrv-5-1-1

10.1210%2Fen.2006-0981

10.1210%2Fen.2005-0610